BNP PARIBAS ARBITRAGE/CALL/MODERNA/130/0.1/20.09.24 | Market Closed - Euronext Paris 17:30:01 23/05/2024 BST | ||
| 4.065 EUR | +12.76% |
|
| Current month | +265.73% | ||
| 1 month | +335.20% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 4.065 | +12.76% |
| 22/05/24 | 3.605 | +55.72% |
| 21/05/24 | 2.315 | +0.87% |
| 20/05/24 | 2.295 | +21.11% |
| 17/05/24 | 1.895 | +2.16% |
Real-time Euronext Paris
Last update May 23, 2024 at 05:30 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| 6N2NB | |
| ISIN | NLBNPFR1YRI3 |
| Date issued | 27/02/2024 |
| Strike | 130 $ |
| Maturity | 20/09/2024 (120 Days) |
| Parity | 10 : 1 |
| Emission price | 0.48 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.075 € |
|---|---|
| Lowest since issue | 0.6 € |
| Spread | 0.01 € |
| Spread % | 0.25% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
163.3
USD
Average target price
138.5
USD
Spread / Average Target
-15.19%
- Stock Market
- Warrants
- 6N2NB Warrant
